Andarix Pharmaceuticals to Present at Neosynth Breast Cancer Conference

On April 25, 2019 Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer reported that it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th 2019 (Press release, Andarix Pharmaceuticals, APR 25, 2019, View Source [SID1234535414]).
The presentation will address the ability of theranostic technology to provide personalized medicine to diagnose and treat breast cancer. The three main types of breast cancer are defined by specific biomarkers and are over-expressed in the disease. The Andarix drug Tozaride targets somatostatin receptors on breast cancer cells and represents a new target for breast cancer therapy. The company will present clinical data to support the biomarker application.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About Tozaride
Tozaride is a novel, best-in-class cancer therapy based on a radio-labeled somatostatin peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in advanced lung cancer patients whose disease has continued to progress after failing other therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both lung cancer (SCLC, NSCLC), and pancreatic cancer patients. Along with its companion diagnostic that helps identify patients most likely to respond – those with enough expression of the peptide’s target – Tozaride could provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.